Firebrick Pharma Limited (ASX:FRE – Get Free Report) insider Peter Molloy acquired 500,000 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average price of A$0.06 ($0.04) per share, for a total transaction of A$28,500.00 ($19,000.00).
Firebrick Pharma Price Performance
Firebrick Pharma Company Profile
Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Recommended Stories
- Five stocks we like better than Firebrick Pharma
- How to Find Undervalued Stocks
- RXO Shares Surge Following New Acquisition Deal
- What is the Nikkei 225 index?
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Firebrick Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firebrick Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
